According to the World Health Organization, as of September 2021, over 264 million people globally were estimated to be living with depression, and about 45 million people were estimated to have bipolar disorder. Trends are increasing year by year.
The diagnosis and treatment of depression and bipolar disorder has witnessed significant growth in recent years due to increasing awareness, acceptance, and the impact of the pandemic.
The mission of Superior Genomics is to improve patient care by providing objective tests that accurately diagnose
mental health disorders.
Superior Genomics is an early-stage health technology company headquartered in Norway, Michigan that is developing innovative solutions to accurately diagnose depressive symptoms as Bipolar Disorder or Major Depressive Disorder through diagnostic blood testing.
In collaboration with Paradise Genomics, Dr. David Van Holla has achieved a significant breakthrough in mental health by discovering gene expression bioprofiles in blood for Major Depressive Disorder (MDD) and Bipolar Disorder (BD). Superior Genomics was created to bring the first objective mental health blood test to the clinic.
Superior Genomics
640 Main Street
Norway, MI 49870
davidvanholla@superiorgenomics.com
(906) 779-7001
(906) 221-1001